CA3215723A1 - Diagnostic methods of prostate cancer - Google Patents

Diagnostic methods of prostate cancer Download PDF

Info

Publication number
CA3215723A1
CA3215723A1 CA3215723A CA3215723A CA3215723A1 CA 3215723 A1 CA3215723 A1 CA 3215723A1 CA 3215723 A CA3215723 A CA 3215723A CA 3215723 A CA3215723 A CA 3215723A CA 3215723 A1 CA3215723 A1 CA 3215723A1
Authority
CA
Canada
Prior art keywords
psma
radioligand
pet
imaging agent
imaging
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3215723A
Other languages
English (en)
French (fr)
Inventor
Ana CATAFAU
Elisabet PARERA PIELLA
Beilei HE
Euloge KPAMEGAN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Advanced Accelerator Applications SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG, Advanced Accelerator Applications SA filed Critical Novartis AG
Publication of CA3215723A1 publication Critical patent/CA3215723A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0402—Organic compounds carboxylic acid carriers, fatty acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
    • A61K51/121—Solutions, i.e. homogeneous liquid formulation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Optics & Photonics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Physics & Mathematics (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dispersion Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
CA3215723A 2021-04-02 2022-04-01 Diagnostic methods of prostate cancer Pending CA3215723A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP21305432 2021-04-02
EP21305432.3 2021-04-02
PCT/EP2022/058754 WO2022207906A1 (en) 2021-04-02 2022-04-01 Diagnostic methods of prostate cancer

Publications (1)

Publication Number Publication Date
CA3215723A1 true CA3215723A1 (en) 2022-10-06

Family

ID=75588163

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3215723A Pending CA3215723A1 (en) 2021-04-02 2022-04-01 Diagnostic methods of prostate cancer

Country Status (9)

Country Link
US (1) US20240181092A1 (cg-RX-API-DMAC7.html)
EP (1) EP4313175A1 (cg-RX-API-DMAC7.html)
JP (1) JP2024514293A (cg-RX-API-DMAC7.html)
KR (1) KR20230165761A (cg-RX-API-DMAC7.html)
CN (1) CN117120100A (cg-RX-API-DMAC7.html)
CA (1) CA3215723A1 (cg-RX-API-DMAC7.html)
IL (1) IL307381A (cg-RX-API-DMAC7.html)
TW (1) TW202304531A (cg-RX-API-DMAC7.html)
WO (1) WO2022207906A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3972627A4 (en) 2019-05-20 2023-06-21 Endocyte, Inc. Methods for preparing psma conjugates
WO2022106629A1 (en) 2020-11-19 2022-05-27 Novartis Ag Synthesis of prostate specific membrane antigen (psma) ligands
CN120897762A (zh) * 2023-04-12 2025-11-04 康奈尔大学 用于治疗癌症的放射治疗缀合物
WO2026027442A1 (en) 2024-08-01 2026-02-05 Novartis Ag Synthesis of a precursor of radiopharmaceutical products

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013173630A1 (en) * 2012-05-16 2013-11-21 Cancer Targeted Technology, Llc Formulation of radiopharmaceuticals containing multiple acidic groups
WO2013173583A1 (en) 2012-05-16 2013-11-21 Cancer Targeted Technology, Llc Psma inhibitors
SMT202300035T1 (it) * 2013-03-15 2023-05-12 Cancer Targeted Tech Llc Metodi per preparare agenti di pet imaging marcati con 18f indirizzati al psma e metodi diagnostici con gli stessi
KR20240027896A (ko) * 2017-07-28 2024-03-04 테크니쉐 우니베르지테트 뮌헨 이중 모드 방사성 트레이서 및 치료법

Also Published As

Publication number Publication date
TW202304531A (zh) 2023-02-01
CN117120100A (zh) 2023-11-24
JP2024514293A (ja) 2024-04-01
WO2022207906A1 (en) 2022-10-06
IL307381A (en) 2023-11-01
KR20230165761A (ko) 2023-12-05
EP4313175A1 (en) 2024-02-07
US20240181092A1 (en) 2024-06-06

Similar Documents

Publication Publication Date Title
EP4313175A1 (en) Diagnostic methods of prostate cancer
Bhattacharyya et al. Zirconium-89 labeled panitumumab: a potential immuno-PET probe for HER1-expressing carcinomas
US20250025584A1 (en) Radiopharmaceutical treatment methods and use
La et al. Progress of coordination and utilization of zirconium-89 for positron emission tomography (PET) studies
Ilem-Ozdemir et al. Nuclear medicine and radiopharmaceuticals for molecular diagnosis
Higuchi et al. Norepinephrine transporter–targeted cancer theranostics—new horizons
US20250269073A1 (en) [177lu] lutetium-psma i&t composition and dosimetry, kit, method of making, and method of using thereof
RU2702294C1 (ru) Способ радионуклидной диагностики операбельного рака молочной железы с гиперэкспрессией Her2/neu
Vernekar et al. Radiopharmaceuticals: a new vista for diagnosis and treatment of thyroid cancer
Torres et al. State of the art and future perspectives of new radinuclides in Nuclear Medicine: Part III
Ruangma et al. PSMA for PET imaging of prostate cancer
AU2018381046B2 (en) Radiolabeled progastrin in cancer diagnosis
Rudd Looking backward to move forward: A chemist’s perspective on the future of radiopharmaceuticals
US20240042067A1 (en) [177lu] lutetium-psma i&t composition, kit, method of making, and method of using thereof
Young Imaging and therapeutic radiotracers for prostate cancer
US20250032651A1 (en) [177lu] lutetium-psma i&t composition and dosimetry, kit, method of making, and method of using thereof
Lucignani Non-standard PET radionuclides: time to get ready for new clinical PET strategies
Bailey Advancing targeting radiopharmaceuticals for theranostic applications
Elison et al. ANZSNM ASM 2021 POSTER PRESENTATIONS
PART growth factor (anti-VEGF), antiepidermal growth
WO2026019453A1 (en) [177lu]lutetium-psma i&t composition and dosimetry, kit, method of making, and method of using thereof
Pascoe et al. Clinical Applications of Nuclear Medicine
Rose et al. Imaging with radionuclides

Legal Events

Date Code Title Description
MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD

Year of fee payment: 3

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20241224

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20241224

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20241224

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD

Year of fee payment: 4

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20260317

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20260317

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED

Effective date: 20260327

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20260327

D00 Search and/or examination requested or commenced

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20260408

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT

Effective date: 20260408

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260408